^{This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.}

Agenda (all times EST)

Thursday 25th March 2021

10.00am EST Introduction Day 1: Gareth Morgan & Kenneth Anderson

10.00-11.30 Session 1: Genetics of drug resistance and high-risk | Chairs: Gareth Morgan & Irene M. Ghobrial

• Overview lecture: Drug-resistant and high-risk MM; Gareth Morgan
• Genomics of SMM; Irene Ghobrial
• Molecular definitions of high-risk; Leif Bergsagel
• Melphalan signatures; Francesco Maura
• Genomics of relapse; Niels Weinhold
• Segmentation at presentation and relapse; Jonathon Keats
• Genetic resistance to IMiDs; Sarah Gooding

11.30-12.15 Panel Discussion: Genetics of drug resistance and high-risk MM

Panel Chairs; Gareth Morgan, Irene M. Ghobrial, Ola Landgren, Jonathan Keats, Leif Bergsagel, Francesco Maura, Niels Weinhold, Saad Usmani.

Discussion points:

• Standardizing the definition of high-risk
• Criteria for molecular markers
• Incorporating markers into trials
• Standardized treatment HR
• Drug resistance and its management

12.15-13:45 Session 2: Management of older, frail, and SMM patients  | Chairs: Maria-Victoria Mateos & Charlotte Pawlyn

• Overview lecture: The clinical management of older patients; Sonja Zweegman    
• Is there a role for genetic assessment in older patients; Eileen Boyle
• Design of elderly trials and geriatric risk scores; Charlotte Pawlyn
• Mass spec for monitoring MRD; Angela Dispenzieri
• Interventions and update on current clinical trials for SMM; Maria-Victoria Mateos
• iStopMM; Sigurdur Kristinsson
• The of anti-CD38 for amyloid. Suzanne Lentzsch

13.45-14.30 Panel Discussion: The clinical management of older frail and SMM patients

Panel Chairs: Maria-Victoria Mateos, Charlotte Pawlyn, Suzanne Lentzsch, Sonja Zweegman, Eileen Boyle, Graham Jackson, Alessandra Larocca, Sigurdur Kristinsson, Angela Dispenzieri.

Discussion points:

• Geriatric assessments and molecular assessments
• What is the age cut-point for aggressive treatment?
• Drug regimens for the elderly
• Treating the frail

Friday 26th March 2021

10.00am EST Introduction Day 2: Gareth Morgan

10.30-11:30 Session 3: The clinical application of T-cell engagers in MM  | Chairs: Kenneth Anderson & Hermann Einsele

• Overview lecture: The clinical application of T-cell engagers in MM; Ajai Chiari
• Role of BCMA targeted ADC and bi-specifics; Sagar Lonial
• Available targets and overview of CAR-T; Ruben Niezwisky
• Deletions of BCMA as a marker of resistance; Leo Rasche
• Can TCE overcome high-risk; Rafael Fonseca
• Early and late complications of TCE including CAR-T and bispecifics; Samir Parekh
• Combination immunotherapies; Ken Anderson

11.30-12.45 Panel Discussion: The clinical application of T-cell engagers in MM

Panel Chairs: Kenneth Anderson, Hermann Einsele, Sagar Lonial, Niels van den Donk, Ruben Niezwisky, Leo Rasche, Adam Cohen, Al Garfell, Ajai Chiari

Discussion points:

• CAR-T vs bispecifics: is there adequate evidence to suggest which is most active?
• Cost vs. efficacy
• Will TCE replace or improve ASCT?

Saturday 27th March 2021

10.00am EST Introduction Day 3: Keith Stewart

10.10-11:40 Session 5: The development and integration of novel targets  | Chairs: Jonathan Kaufman & Keith Stewart

• Overview lecture: The development and integration of novel targets; Keith Stewart 
• Mass spec for monitoring MRD; Angela Dispenzieri
• MCL1, BCL2 inhibition and 1q amp; Larry Boise
• Resistance to protein degraders; Constantine Mitsiades
• MRD, Master study and therapy cessation; Luciano Costa
• Biology of residual clones; Bruno Paiva
• antiCD38 combinations; Peter Voorhees
• Nuclear exportin inhibitors; Nizar Bahlis

14:30 EST Summary and close of iwMyeloma 2021 | Chairs: Gareth Morgan & Ken Anderson

^{This event is for hematologists, researchers, nurses, and allied medical professionals only. Please apply for registration by filling in the form and confirming your details. We will review your application and confirm your registration on submission. By applying, you confirm that your details are correct and that the organizer can communicate with you regarding this event.}